Anti-CD20 Bispecifics Could Find Niche In First-Line Lymphoma

Highly Entrenched Rituxan Could Prove Tough To Dislodge

Roche presented data at ASCO on its two CD20-targeting bispecific antibodies, showing high response rates in heavily pretreated non-Hodgkin lymphoma patients.

Cancer-cells-pink-color_1200x675
Roche presented data at ASCO on its two CD20xCD3-targeting bispecific antibodies • Source: Shutterstock

With high response rates in heavily pretreated non-Hodgkin’s lymphoma (NHL) patients, Roche Holding AG hopes to eventually move its CD20-targeting bispecific antibodies mosunetuzumab and glofitamab into earlier lines of therapy, where they could potentially replace long-established anti-CD20 monoclonal antibody players like its own Rituxan (rituximab) and Gazyva (obinutuzumab). But it’s more likely that the bispecifics will fit into certain niches of diffuse large B-cell lymphoma (DLBCL) patients who do not respond well to Rituxan/chemotherapy approaches.

Rituxan has long been a dominant force in NHL and similar cancers and will be a hard drug to unseat,...

More from ASCO

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By 

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

More from Conferences